An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Stead, Lucy F ^a   Egan, Philip ^a   Devery, Aoife ^b   Conway, Caroline ^a   Daly, Catherine ^a   Berri, Stefano ^a   Wood, Henry ^a   Belvedere, Ornella ^a   Papagiannopoulos, Kostas ^c   Ryan, Anderson ^b   Rabbitts, Pamela ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P53; TRANSCRIPTOME;

ALLELIC IMBALANCE; ARTICLE; CELL ACTIVITY; CELL STRAIN LUDLU 1; CELL STRUCTURE; CONTROLLED STUDY; DNA REPAIR; DRUG SENSITIVITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GERM LINE; HUMAN; HUMAN CELL; HUMAN GENOME; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; NEXT GENERATION SEQUENCING; RADIOSENSITIZATION; SEQUENCE ANALYSIS; SOMATIC MUTATION; TOBACCO; TP53 GENE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84892918222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078823     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90.
2. International Agency for Research on Cancer (IARC) (2007) Cancer Incidence in Five Continents, Vol 9.
3. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
4. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, et al. (2010) Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine 2: 62ra93-62ra93.
5. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute 97: 339-346.
6. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, et al. (2010) A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190.
7. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, et al. (2010) The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465: 473-477.
8. The Cancer Genome Atlas (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
9. Nik-Zainal S, Alexandrov Ludmil B, Wedge David C, Van Loo P, Greenman Christopher D, et al. (2012) Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell 149: 979-993.
10. Stead LF, Berri S, Wood HM, Egan P, Conway C, et al. (2012) The transcriptional consequences of somatic amplifications, deletions and rearrangements in a human lung squamous cell carcinoma. Neoplasia 12: 1075-1086.
11. Hackenberg M, Sturm M, Langenberger D, Falcon-Perez JM, Aransay AM (2009) miRanalyzer: a microRNA detection and analysis tool for next-generation sequencing experiments. Nucleic Acids Research 37: W68-W76.
12. Complete Genomics Incorporated. (2012) cgatools Methods software v1.3.0.
13. Flicek P, Amode MR, Barrell D, Beal K, Brent S, et al. (2011) Ensembl 2011. Nucleic Acids Research 39: D800-D806.
14. Paşaniuc B, Zaitlen N, Halperin E (2011) Accurate Estimation of Expression Levels of Homologous Genes in RNA-seq Experiments. Journal of Computational Biology 18: 459-468.
15. Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, et al. (2009) Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25: 2744-2750.
16. Goya R, Sun MGF, Morin RD, Leung G, Ha G, et al. (2010) SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 26: 730-736.
17. Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, et al. (2010) Tumor Transcriptome Sequencing Reveals Allelic Expression Imbalances Associated with Copy Number Alterations. PLoS ONE 5: e9317.
18. Roberts A, Pimentel H, Trapnell C, Pachter L (2011) Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics.
19. Grenman R, Burk D, Virolainen E, Buick R, Church J, et al. (1989) Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136.
20. Thilly W, Deluca J, Furth E, Hoppe HI, Krolewski J, et al. (1980) Gene-locus mutation assays in diploid human lymphoblast lines. Chemical mutagens: Principles and methods for their detection. New York: Plenum Press.
21. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protocols 1: 2315-2319.
22. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research 39: D945-D950.
23. Joerger AC, Fersht AR (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26: 2226-2242.
24. Song H, Hollstein M, Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9: 573-580.
25. Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks. Molecular Cell 7: 263-272.
26. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, et al. (2012) Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Research.
27. Pfeifer G, Denissenko M, Olivier M, Tretyakova N, Hecht S, et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. ONCOGENE 21: 17.
28. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, et al. (2005) TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers. Cancer Research 65: 5076-5083.
29. Hainaut P, Pfeifer GP (2001) Patterns of p53 G'ÜíT transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22: 367-374.
30. Yoon J-H, Smith LE, Feng Z, Tang M-s, Lee C-S, et al. (2001) Methylated CpG Dinucleotides Are the Preferential Targets for G-to-T Transversion Mutations Induced by Benzo[a]pyrene Diol Epoxide in Mammalian Cells. Cancer Research 61: 7110-7117.
31. Xiao S-J, Zhang C, Zou Q, Ji Z-L (2010) TiSGeD: a database for tissue-specific genes. Bioinformatics 26: 1273-1275.
32. Faghihi MA, Wahlestedt C (2009) Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol 10: 637-643.
33. Li K, Ramchandran R (2010) Natural Antisense Transcript: A Concomitant Engagement with Protein-Coding Transcript. Oncotarget; Vol 1, No 6: October 2010.
34. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
35. The Cancer Genome Project (2012) Cancer Gene Census.
36. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, et al. (2010) Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. Cancer Research 70: 2789-2798.
37. The MARIE-GENICA Consortium (2010) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Research and Treatment 120: 10.
38. Johnson N, Fletcher O, Palles C, Rudd M, Webb E, et al. (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Human Molecular Genetics 16: 1051-1057.
39. Shen H, Zhu Y, Wu Y-j, Qiu H-r, Shu Y-q (2008) Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genetics and Cytogenetics 181: 100-107.
40. Han Y-Y, Davis DL, Weissfeld JL, Dinse GE (2010) Generational risks for cancers not related to tobacco, screening, or treatment in the United States. Cancer 116: 940-948.
41. Boffetta P, Järvholm B, Brennan P, Nyrén O (2001) Incidence of lung cancer in a large cohort of non-smoking men from Sweden. International Journal of Cancer 94: 591-593.
42. Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers - a different disease. Nat Rev Cancer 7: 778-790.
43. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, et al. (2007) Lung Cancer Incidence in Never Smokers. Journal of Clinical Oncology 25: 472-478.
44. Thu KL, Vucic EA, Chari R, Zhang W, Lockwood WW, et al. (2012) Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability. PLoS ONE 7: e33003.
45. Ju YS, Lee W-C, Shin J-Y, Lee S, Bleazard T, et al. (2011) Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Research.
46. Lewis SJ, Cherry NM, McL. Niven R, Barber PV, Wilde K, et al. (2003) Cotinine levels and self-reported smoking status in patients attending a bronchoscopy clinic. Biomarkers 8: 218-228.
47. Heller W-D, Scherer G, Sennewald E, Adlkofer F (1998) Misclassification of Smoking in a Follow-up Population Study in Southern Germany. Journal of Clinical Epidemiology 51: 211-218.
48. Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, et al. (2013) Signatures of mutational processes in human cancer. Nature.
49. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, et al. (2012) Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. The Journal of Pathology 227: 53-61.
50. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, et al. (2010) An Integrated Approach to Uncover Drivers of Cancer. Cell 143: 1005-1017.
51. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
52. Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, et al. (1997) Differential Contributions of BRCA1 and BRCA2 to Early-Onset Breast Cancer. New England Journal of Medicine 336: 1416-1422.
53. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, et al. (1997) The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 336: 1401-1408.
54. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, et al. (2000) Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer. JAMA: The Journal of the American Medical Association 283: 2260-2265.
55. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, et al. (1994) Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer. Nature 368: 258-261.
56. de Marinis F, Grossi F (2008) Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer. The Oncologist 13: 14-20.
57. Stordal B, Davey M (2007) Understanding cisplatin resistance using cellular models. IUBMB Life 59: 696-699.
58. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, et al. (2008) Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin. Clinical Cancer Research 14: 3916-3925.
59. Biesecker L, Shianna K, Mullikin J (2011) Exome sequencing: the expert view. Genome Biology 12: 128.